Next Article in Journal
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
Previous Article in Journal
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Previous Article in Special Issue
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy
Article Menu

Export Article

Open AccessReview
Vaccines 2015, 3(2), 344-372; doi:10.3390/vaccines3020344

Whole Tumor Antigen Vaccines: Where Are We?

1
Ovarian Cancer Research Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
2
Ludwig Cancer Center, University of Lausanne, Lausanne 1011, Switzerland
3
Center of Experimental Therapeutics, Ludwig Cancer Center, University of Lausanne, Lausanne 1011, Switzerland
*
Authors to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Received: 8 January 2015 / Revised: 13 April 2015 / Accepted: 16 April 2015 / Published: 23 April 2015
(This article belongs to the Special Issue Dendritic Cell Vaccine)
View Full-Text   |   Download PDF [444 KB, uploaded 23 April 2015]   |  

Abstract

With its vast amount of uncharacterized and characterized T cell epitopes available for activating CD4+ T helper and CD8+ cytotoxic lymphocytes simultaneously, whole tumor antigen represents an attractive alternative source of antigens as compared to tumor-derived peptides and full-length recombinant tumor proteins for dendritic cell (DC)-based immunotherapy. Unlike defined tumor-derived peptides and proteins, whole tumor lysate therapy is applicable to all patients regardless of their HLA type. DCs are essentially the master regulators of immune response, and are the most potent antigen-presenting cell population for priming and activating naïve T cells to target tumors. Because of these unique properties, numerous DC-based immunotherapies have been initiated in the clinics. In this review, we describe the different types of whole tumor antigens that we could use to pulse DCs ex vivo and in vivo. We also discuss the different routes of delivering whole tumor antigens to DCs in vivo and activating them with toll-like receptor agonists. View Full-Text
Keywords: vaccines; dendritic cells; whole tumor; personalized vaccines vaccines; dendritic cells; whole tumor; personalized vaccines
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chiang, C.L.-L.; Coukos, G.; Kandalaft, L.E. Whole Tumor Antigen Vaccines: Where Are We? Vaccines 2015, 3, 344-372.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top